Article 59BR7 Trial to deliberately infect people with coronavirus draws mixed reaction

Trial to deliberately infect people with coronavirus draws mixed reaction

by
Beth Mole
from Ars Technica - All content on (#59BR7)
GettyImages-1228406732-800x533.jpg

Enlarge / Woman receives an experimental COVID-19 vaccine at the University of Massachusetts Medical School in Worcester, MA, on September 04, 2020, as part of a clinical trial. (credit: Getty | Boston Globe)

Researchers in the United Kingdom plan to begin intentionally infecting a small batch of healthy young people with the novel coronavirus in January as part of a first human challenge trial," according to an announcement Monday.

The plan has not yet been approved by the Medicines and Healthcare Regulatory Agency (MHRA), which regulates clinical trials in the UK, and outside experts have had mixed reactions to the announcement so far.

Nevertheless, the UK government is planning to invest $43.4 million (33.6 million pounds) in the trials. Researchers meanwhile are preparing to recruit an initial 30 to 50 people, aged 18 to 30, who have no underlying health conditions. Those conditions include diabetes, heart disease, or obesity, all of which would put them at greater risk of the pandemic coronavirus, SARS-CoV-2, and the disease it causes, COVID-19.

Read 16 remaining paragraphs | Comments

index?i=W61B3n3uw1w:6CldwwnXi5k:V_sGLiPB index?i=W61B3n3uw1w:6CldwwnXi5k:F7zBnMyn index?d=qj6IDK7rITs index?d=yIl2AUoC8zA
External Content
Source RSS or Atom Feed
Feed Location http://feeds.arstechnica.com/arstechnica/index
Feed Title Ars Technica - All content
Feed Link https://arstechnica.com/
Reply 0 comments